InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,265.94
(
0.28%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119891
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Thursday, 06/28/2007 12:03:33 PM

Thursday, June 28, 2007 12:03:33 PM

Post# of 19309
Pharming held a meeting for investors today
including an overview of the company’s
development programs. The presentation slides
will be posted on the company’s website.

http://biz.yahoo.com/iw/070628/0272261.html

>>
Pharming Provides Portfolio and Technology Update at Company Meeting

Thursday June 28, 7:37 am ET

Leiden, The Netherlands, June 28, 2007. Biotech company Pharming Group NV ("Pharming" or "the Company") (Euronext: PHARM) will present an update of its portfolio of products and technologies during a meeting for analysts and specialized reporters today commencing at 1:30 pm CET.

Dr. Jan Hoeijmakers, member of Pharming's Scientific Advisory Board and professor at the Erasmus Medical Center in Rotterdam, will provide an overview of the current state of the art in the field of DNA-damage and repair. In particular, the link between DNA-damage and ageing will be highlighted. Recent scientific results and their impact on developing therapies for ageing diseases will be discussed. Dr. Frank Pieper, Chief Science and Technology Officer, one of the driving forces behind the development of Pharming's transgenic technology, will discuss the science behind the production of proteins in milk.

Dr. Bruno Giannetti, Chief Operations Officer, will present an update on the development of the various products in Pharming's portfolio. With respect to Rhucin®, Pharming's lead product developed as a treatment for heredetary angioedema ("HAE"), Dr. Giannetti will review the clinical program and summarize the relevant data generated so far. He will confirm that the product appears to be safe, well-tolerated and provides rapid relief to patients suffering from acute HAE attacks. He will also discuss the scientific and clinical rationale in developing the product for other indications, in particular for transplantation.

With respect to Pharming's lactoferrin product, Dr. Giannetti will confirm that the product has an excellent safety profile with no significant toxicity observed so far after considerable testing. In very recent interactions with the US-FDA, who are reviewing the dossier in relation to Pharming's request to obtain GRAS ("Generally Recognized As Safe") status, it appears that there are no further questions outstanding, and that the FDA will communicate on possible next steps with GRAS review of lactoferrin in the third quarter of 2007. Pharming expects that a final opinion by the FDA will be provided to Pharming later this year.

On Pharming's fibrinogen product, Dr. Giannetti will confirm efforts to develop fibrinogen as a pharmaceutical product for the treatment of bleeding disorders, along with its development for medical device applications in partnership with third parties. The Company expects to provide further details on the pharmaceutical applications of fibrinogen and its development in the second half of 2007.

The commercial outlook for the Company, although not on the agenda of today's meeting, remains positive with the main product- development related events anticipated for the second half of 2007 being presentation of results from the clinical trials of Rhucin® for HAE, the opinion of the European authorities (EMEA) on market authorization of Rhucin® in Europe, the opinion of FDA on GRAS status of lactoferrin, and clinical development of Rhucin® for new indications.

The presentation made at the meeting of today will be made available on the website of the Company (www.pharming.com) after the meeting has ended.

Background on Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (MAA under review by EMEA) and human lactoferrin for use in food products (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of tissue repair (via its collaboration with NovaThera) and DNA repair (via its acquisition of DNage). Additional information is available on the Pharming website, http://www.pharming.com and on http://www.dnage.nl .
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up